GEMMABio, a new therapeutics company, will serve as the research and innovation arm to speed the research of and global access to life-changing advanced therapies for those living with rare diseases.
Alongside Franklin Biolabs, GEMMABio will advance gene therapy research and deliver therapeutics to patients around the world significantly faster.
Company Details
- Employees
- 64
- Founded
- -
- Address
- 125 S 31st St, Philadelphia,pennsylvania 19104,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.gemmabiotx.com/
- Keywords
- Gene Therapy, Rare Disease, Quality Assurance, GXP operations, Regulatory affairs, Clinical development, Discovery research, Translational research, Vector research, Biomedical research, Orphan disease, Genetic disease, Genetic medicine, AAV vectors, Bioinformatics, Capsid engineering, Genome editing.
- HQ
- Philadelphia, Pennsylvania
Gemma Biotherapeutics Questions
Gemma Biotherapeutics's website is https://www.gemmabiotx.com/
Gemma Biotherapeutics's LinkedIn profile is https://www.linkedin.com/company/gemmabiotx
Gemma Biotherapeutics has
64 employees.
View email and phone details for 64
employees at Gemma Biotherapeutics.
Gemma Biotherapeutics's industry is
Biotechnology Research
Gemma Biotherapeutics's top competitors are
Franklin Biolabs,
Iecure, Inc.,
Tolerance Bio,
Spark Therapeutics, Inc.,
Gene Therapy Program | University Of Pennsylvania,
Myrtelle,
Legend Biotech,
Iovance Biotherapeutics, Inc.,
Verismo Therapeutics,
Interius Biotherapeutics.
Gemma Biotherapeutics's categories are Biotechnology Research
Gemma Biotherapeutics's founding year is 2024
